A phase III clinical trial is currently ongoing to evaluate the clinical efficacy of ivosidenib and enasidenib with intensive induction and as maintenance therapy for patients with IDH1/IDH2-mutated AML (NCT03839771). The gene discussed is IDH1; the disease is acute myeloid leukemia.